FC
VRTX icon

Farringdon Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Farringdon Capital’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,831
Closed -$818K – 440
2026
Q1 		$818K Buy
+1,831
New +$854K 0.18% 159
2025
Q2 		– Sell
-1,341
Closed -$650K – 606
2025
Q1 		$650K Buy
+1,341
New +$625K 0.33% 72

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Farringdon Capital's VRTX Position: Q2 2026 in Review

Farringdon Capital sold out of Vertex Pharmaceuticals (VRTX) in Q2 2026, closing a stake of 1,831 shares — an estimated $818K sold.

Farringdon Capital first reported a position in VRTX in Q1 2025 and held it in 2 quarters. The position peaked at $818K in Q1 2026. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Farringdon Capital reported no remaining Vertex Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Farringdon Capital sold 1,831 Vertex Pharmaceuticals shares in Q2 2026, an estimated $818K.
  • Farringdon Capital first reported a position in Vertex Pharmaceuticals in Q1 2025 and held it in 2 quarters.
  • Farringdon Capital's Vertex Pharmaceuticals position peaked at $818K in Q1 2026.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Farringdon Capital's 13F filing for Q2 2026, filed 12 Aug 2026.